Business Wire

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Nasdaq

Erasca, Inc. Reports Promising Preclinical Data on ERAS-0015 and ERAS-4001 Targeting RAS/MAPK Pathway at AACR Annual Meeting

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Seeking Alpha

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
BioWorld

RMC-7977 targets RAS/MAPK pathway and sensitizes AML cells

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...
ascopubs.org

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...